Yonjin Capital

Yonjin Capital is a prominent international investment firm specializing in early- and mid-stage life science companies, focusing on therapeutics, diagnostics, and medical devices. The firm operates as the North America and Europe investment arm of Yonjin Group, a China-based conglomerate headquartered in Shanghai, and is the sister firm of Yonghua Capital. With a team possessing extensive global knowledge and networks, Yonjin Capital aims to help portfolio companies achieve remarkable results.

Established in 2016, Yonjin Capital is headquartered in Cambridge, Massachusetts, United States. The firm invests in innovative biotech companies seeking to advance new technologies in healthcare and life sciences. Its portfolio includes companies like Rapafusyn Pharmaceuticals, which closed an over-subscribed $44 million Series A financing round in September 2025, with Yonjin Capital participating alongside other investors.

Yonjin Capital's investment strategy emphasizes long-term partnerships, deep operational engagement, and honoring the core values of businesses while preparing them for future growth. The firm's guiding principles include principled equity, acquired genius, radical collaboration, and abundant prosperity, aiming to create value that benefits every stakeholder involved.